In The News,
Lindsay Bealor Greenleaf talks with Managed Healthcare Executive about the administration’s drug pricing proposals’ potential impact on managed care
[el-text]
Written by Tracey Walker
***excerpt***
Lindsay Bealor Greenleaf, director at healthcare advisory firm ADVI Health, says of most note to managed care, the Administration seeks comment on how the elimination of the copay coupon exclusion from Average Manufacturer Price (AMP) and Medicaid Best Price determinations would affect drug prices. “If this policy change is enacted, manufacturer discounts provided through copay coupons would be treated the same as other discounts and rebates, and thereby serve to lower a drug’s AMP and Best Price,” she says. “This policy change could effectively eliminate the financial incentive to provide copay coupons.”
***end excerpt***
***
[/el-text]